1h Free Analyst Time
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.Speak directly to the analyst to clarify any post sales queries you may have.
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Undisclosed which include indications Depression, Treatment Resistant Depression, Major Depressive Disorder, Schizophrenia, Anxiety Disorders, Cognitive Impairment, DiGeorge Syndrome, Drug Addiction, Neurodegenerative Diseases, Unspecified and Unspecified Neurologic Disorders.
The latest report Metabotropic Glutamate Receptor 3 - Drugs In Development, 2022, outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Camino Pharma LLC
- Denovo Biopharma LLC
- Eli Lilly and Co
- Nobias Therapeutics Inc
- Noema Pharma AG
- Sumitomo Pharma Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles
- DSP-3456 - Drug Profile
- Product Description
- Mechanism Of Action
- LY-3020371 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mGlu3 PAM - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NB-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NOE-109 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pomaglumetad methionil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SBP-9881 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TS-134 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TS-161 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VU-0092273 - Drug Profile
- Product Description
- Mechanism Of Action
- VU-0650786 - Drug Profile
- Product Description
- Mechanism Of Action
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products
- Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones
- Featured News & Press Releases
- Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
- Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
- Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research
- Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Addex Therapeutics Ltd, 2022
- Pipeline by Camino Pharma LLC, 2022
- Pipeline by Denovo Biopharma LLC, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by Nobias Therapeutics Inc, 2022
- Pipeline by Noema Pharma AG, 2022
- Pipeline by Sumitomo Pharma Co Ltd, 2022
- Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Addex Therapeutics Ltd
- Camino Pharma LLC
- Denovo Biopharma LLC
- Eli Lilly and Co
- Nobias Therapeutics Inc
- Noema Pharma AG
- Sumitomo Pharma Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
